Codaccioni J L, Orgiazzi J, Blanc P, Pugeat M, Roulier R, Carayon P
Endocrinologie et Maladies Métaboliques, Hôpital de la Conception, Marseille, France.
J Clin Endocrinol Metab. 1988 Oct;67(4):656-62. doi: 10.1210/jcem-67-4-656.
Twenty-six patients with Graves' hyperthyroidism treated only with propranolol for 1-21 months have been followed up to 5 years. The patients were evaluated before treatment, at 15, 30, and 90 days during treatment, and then at 90-day intervals during propranolol treatment by clinical examination and measurement of serum free T3, free T4, rT3, TSH, and sex hormone-binding globulin concentrations and serum anti-thyroglobulin, antithyroid microsomal, antithyroid peroxidase, and thyroid-stimulating autoantibodies. Eighteen patients who had no biochemical improvement during propranolol therapy or relapsed after initial improvement were treated conventionally. In contrast, eight patients had a biochemical remission, which has lasted 30-48 months after propranolol withdrawal. The biochemical values before and during treatment did not differ among the two groups of patients, except for the initial serum free T3 levels which were significantly higher in the patients who had no remission. Serum TSH levels returned to normal only in patients who had a long-lasting remission. While thyroid autoantibodies decreased or disappeared during follow-up, the evolution of thyroid-stimulating autoantibody values was grossly related to the clinical outcome. Long-lasting remissions may occur in patients with hyperthyroidism due to Graves' disease not given ablative or antithyroid drug therapy. Since propranolol is devoid of antithyroid and immunosuppressive actions, these remissions are probably spontaneous. Although they tended to occur in patients with less severe disease, no biological parameter was found that predicted the outcome.
26例仅用普萘洛尔治疗1 - 21个月的格雷夫斯甲亢患者随访了5年。在治疗前、治疗期间的第15、30和90天以及在普萘洛尔治疗期间每隔90天,通过临床检查和测定血清游离T3、游离T4、反T3、促甲状腺激素(TSH)、性激素结合球蛋白浓度以及血清抗甲状腺球蛋白、抗甲状腺微粒体、抗甲状腺过氧化物酶和甲状腺刺激自身抗体对患者进行评估。18例在普萘洛尔治疗期间无生化改善或在初始改善后复发的患者接受了常规治疗。相比之下,8例患者出现了生化缓解,在停用普萘洛尔后持续了30 - 48个月。两组患者治疗前和治疗期间的生化值除了初始血清游离T3水平在未缓解的患者中显著较高外,并无差异。仅在有长期缓解的患者中血清TSH水平恢复正常。虽然甲状腺自身抗体在随访期间下降或消失,但甲状腺刺激自身抗体值的变化与临床结果密切相关。未接受消融或抗甲状腺药物治疗的格雷夫斯病甲亢患者可能会出现长期缓解。由于普萘洛尔没有抗甲状腺和免疫抑制作用,这些缓解可能是自发的。虽然它们倾向于发生在病情较轻的患者中,但未发现预测结果的生物学参数。